HANGZHOU SUMGEN BIOTECH CO LTD has a total of 24 patent applications. Its first patent ever was published in 2019. It filed its patents most often in WIPO (World Intellectual Property Organization), Taiwan and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI CO LTD, ICELL GENE THERAPEUTICS LLC and ABCLON INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | Taiwan | 3 | |
#3 | Australia | 2 | |
#4 | Brazil | 2 | |
#5 | Canada | 2 | |
#6 | China | 2 | |
#7 | EPO (European Patent Office) | 2 | |
#8 | Republic of Korea | 2 | |
#9 | Singapore | 2 | |
#10 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Fermentation | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Lv Ming | 22 |
#2 | Tan Bin | 22 |
#3 | Ding Xiaoran | 19 |
#4 | Wang Xuegong | 19 |
#5 | Miao Shiwei | 18 |
#6 | Miao Shi-Wei | 3 |
#7 | Ding Xiao-Ran | 3 |
#8 | Wang Xue-Gong | 3 |
#9 | Xiaoran Ding | 2 |
#10 | Bin Tan | 2 |
Publication | Filing date | Title |
---|---|---|
WO2021032130A1 | Bcma antibody | |
WO2020200256A1 | Fusion protein and use thereof | |
WO2020098672A1 | Fusion protein and use thereof | |
WO2019228345A1 | Antibody binding to axl protein and application thereof | |
CN111989346A | Fusion protein combined with CD47 protein and application thereof | |
KR20200120937A | CD38 protein antibody and uses thereof |